Erythropoietin News and Research

RSS

Erythropoietin, or its alternative erythropoetin or EPO, is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. It is a cytokine for erythrocyte (red blood cell) precursors in the bone marrow.

3SBio first quarter total net revenues increase 24.5% to RMB147.2M

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the first quarter ended March 31, 2012.

14 May 2012

Positive results from PROLOR Biotech's hGH-CTP Phase II trial for growth hormone deficiency

PROLOR Biotech, Inc. today reported top-line results from a Phase II four-month treatment extension study of hGH-CTP, its long-acting version of human growth hormone, in growth hormone deficient adults.

7 May 2012

Nephros granted rights to market products based on Medica's Medisulfone ultrafiltration technology

Nephros, Inc., a medical device company developing and marketing filtration products for therapeutic applications, infection control, and advanced water purification solutions, today announced that the company has entered into a strategic license and supply agreement with Medica S.p.A.

23 Apr 2012

Medgenics seeks FDA Orphan Drug Designation for INFRADURE to treat hepatitis D

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has filed for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for INFRADURE for the treatment of hepatitis D.

23 Apr 2012

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

MSD, known as Merck in the United States and Canada, announced final results from a Phase III, open-label study designed to compare the impact of two anaemia management strategies on sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 1 infection treated with VICTRELIS(boceprevir) in combination with PEGINTRON and ribavirin.

20 Apr 2012

Medgenics seeks IND approval to initiate EPODURE Biopump Phase IIb anemia study in ESRD patients

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has filed an Investigational New Drug application with the U.S. Food and Drug Administration to initiate a Phase IIb multi-center, 100-patient clinical trial.

18 Apr 2012

Akebia completes AKB-6548 Phase 2 study for anemia in CKD patients

Akebia Therapeutics, Inc., a pharmaceutical discovery and development company focused on anemia and vascular disorders, today announced that it has successfully completed a randomized, double-blinded, placebo-controlled Phase 2 dose-ranging study of AKB-6548 in patients with stage 3 and 4 chronic kidney disease (CKD).

6 Apr 2012

Medgenics to commence EPODURE Biopumps Phase IIa study in ESRD-related anemia

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced receipt of clearance from the Israeli Ministry of Health to initiate a Phase IIa clinical study evaluating the safety and efficacy of sustained erythropoietin therapy produced and delivered by the Company's EPODURE Biopumps.

26 Mar 2012

PROLOR commences hGH-CTP Phase II trial in children with GHD

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in children with growth hormone deficiency.

20 Mar 2012

3SBio fourth quarter total net revenues increase 38.2% to RMB139.9M

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced its unaudited financial results for the fourth quarter and full year ended December 31, 2011.

9 Mar 2012

Researchers discover critical placental niche cell and signaling pathway

UCLA stem cell researchers have discovered a critical placental niche cell and signaling pathway that prevent blood precursors from premature differentiation in the placenta, a process necessary for ensuring proper blood supply for an individual's lifetime.

2 Mar 2012

EMA acceptance of peginesatide MAA triggers $5M milestone payment to Affymax

Affymax, Inc. today announced that it will receive a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize peginesatide.

27 Feb 2012

Early MSC transplantation can help repair neonatal brain damage

In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting -, in Dallas, Texas, researchers will report that early transplantation of human placenta-derived mesenchymal stem cells into the lateral ventricles of neonatal rats with birth-related brain damage is possible, and that the donor cells can survive and migrate in the recipient's brain.

13 Feb 2012

Progenitor cells have potential to develop into RBCs

A study of the cells that respond to crises in the blood system has yielded a few surprises, redrawing the 'map' of how blood cells are made in the body.

1 Feb 2012

Array second quarter revenue increases to $23.2 million

Array BioPharma Inc. today reported financial results for the second quarter of fiscal 2012.

31 Jan 2012

Correcting anemia can preserve kidney function in many transplant recipients

Correcting anemia, a red blood cell deficiency, can preserve kidney function in many kidney transplant recipients, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

23 Dec 2011

Positive dose-escalation/expansion data from Array BioPharma's ARRY-614 Phase 1 MDS study

Array BioPharma Inc. today announced positive dose-escalation/expansion data for its novel, small molecule dual p38/Tie2 inhibitor, ARRY-614.

12 Dec 2011

Research: lncRNA affects apoptosis and plays a role in RBC development

A long non-coding RNA (lncRNA) regulates programmed cell death during one of the final stages of red blood cell differentiation, according to Whitehead Institute researchers. This is the first time a lncRNA has been found to play a role in red blood cell development and the first time a lncRNA has been shown to affect programmed cell death.

8 Dec 2011

Growth hormone PDGF-BB and blood protein EPO implicated in development of cancer

Researchers at the Swedish medical university Karolinska Institutet have demonstrated that a growth hormone, PDGF-BB, and the blood protein EPO are involved in the development of cancer tumours and that they combine to help the tumours proliferate in the body.

5 Dec 2011

Akebia commences dosing in AKB-9778 Phase 1 study for diabetic macular edema and retinopathy

Akebia Therapeutics, Inc., a small molecule discovery and development company focused on anemia and vascular disorders, today announced that it has dosed the first subjects in a first-in-man Phase 1 study of AKB-9778, a first-in-class human protein tyrosine phosphatase beta (HPTPβ) inhibitor in development for diabetic macular edema (DME) and diabetic retinopathy (DR).

21 Nov 2011